Cyclacel announces abstracts selected for presentation at American Association for Cancer Research Annual Meeting

Berkeley Heights, NJ, March 29, 2011 – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), announced today that two abstracts highlighting preclinical data for Cyclacel's cell cycle inhibitor drugs have been selected for presentation at the American Association for Cancer Research (AACR) 102nd Annual Meeting, being held from April 2 – 6, 2011, in Orlando, Florida.

The abstracts can be accessed through the AACR website, www.aacr.org. Abstract titles are provided below. Please note that according to AACR policy, all data are embargoed until the time of the beginning of the presentation.

CYC116:

Identification and characterization of potential tumor cell resistance mechanisms towards a novel aurora kinase inhibitor, CYC116 "

Date/Time: Sunday, April 3, 2011, 1:00 PM – 5:00 PM EDT

Abstract Number: 735

Sapacitabine:

"Mechanism-based drug combinations with the DNA-strand-breaking nucleoside analog CNDAC [1] " *

Date/Time: Sunday, April 3, 2011, 4:20 PM – 4:35 PM EDT

Abstract Number: 962

**Note: asterisk denotes research conducted by independent investigators.*

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 3 development for the treatment of acute myeloid leukemia in the elderly under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration, and in Phase 2 studies for myelodysplastic syndromes and lung cancer. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.

Forward-looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words

or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact for Cyclacel Pharmaceuticals, Inc.

Investors/Media:
Corey Sohmer,
(908) 517-7330
csohmer@cyclacel.com

[1] CNDAC is a major metabolite of sapacitabine.